Skip to main content

Mayo Clinic

SEC CIK
0001318153
Latest filing
Nov 12, 2024

The latest 13F from Mayo Clinic covers Q3 2024 (filed Nov 12, 2024): 3 long positions worth $2.90M. The top 10 holdings make up 100.0% of the portfolio, and the largest is iShares Tr at 71.5%. Livermore has 11 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q3 2024

Share counts compared with Q2 2024: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
0
Added
0
Reduced
1
Est. −$44.7K
Sold out
1
Est. −$145.4K

Top 5 holdings

Share of this quarter's portfolio value

  1. iShares Tr464288257
    71.5%$2.08M
  2. ZNTLZentalis Pharmaceuticals, Inc.
    22.2%$644.0KHistory
  3. UBXUnity Biotechnology, Inc.
    6.3%$182.4KHistory

Biggest buys

New and added positions, by estimated amount bought

None this quarter.

Largest weight increases

New and added positions, by percentage points of the portfolio gained

None this quarter.

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. NMTCNeuroone Medical Technologies Corp
    −$145.4KSold outHistory
  2. ZNTLZentalis Pharmaceuticals, Inc.
    −$44.7KReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. NMTCNeuroone Medical Technologies Corp
    −4.80 pp4.8% → 0.0%History
  2. ZNTLZentalis Pharmaceuticals, Inc.
    −3.07 pp25.3% → 22.2%History

Metrics

13F metrics for Q3 2024, computed only from the numbers in the filings. Definitions below.

Portfolio value
$2.90M
−$127.8K (−4.2%) vs. prior quarter
Positions
3
−1 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
0.0%
Q3 2024, one quarter
Average holding period
7.9 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

10 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $188.8M (Q4 2022)

Q1 2021: $86.9MQ2 2021: $90.4MQ4 2022: $188.8MQ1 2023: $121.8MQ2 2023: $97.4MQ3 2023: $51.9MQ4 2023: $16.2MQ1 2024: $6.15MQ2 2024: $3.03MQ3 2024: $2.90M
Q1 2021Q3 2024
13F filings of Mayo Clinic by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q3 2024Nov 12, 20243$2.90MiShares TrZNTLUBXvs. Q2 2024SEC
Q2 2024Aug 12, 20244$3.03MiShares TrZNTLUBXvs. Q1 2024SEC
Q1 2024May 13, 20245$6.15MZNTLiShares TrCATXvs. Q4 2023SEC
Q4 2023Feb 13, 20247$16.2MiShares TrZNTLIMNMvs. Q3 2023SEC
Q3 2023Nov 14, 20239$51.9MiShares TrZNTLBSMvs. Q2 2023SEC
Q2 2023Aug 9, 202311$97.4MiShares TrBSMZNTLvs. Q1 2023SEC
Q1 2023May 5, 202313$121.8MiShares TrBSMZNTLvs. Q4 2022SEC
Q4 2022Feb 9, 2023Amended13$188.8MiShares TrBSMZNTL–SEC
Q2 2021Aug 12, 20219$90.4MBSMZNTLUBXvs. Q1 2021SEC
Q1 2021May 13, 20218$86.9MBSMZNTLUBX–SEC